MASH (metabolic dysfunction-associated steatohepatitis) — formerly called NASH — is the aggressive form of fatty liver disease characterized by inflammation, hepatocyte ballooning injury, and progressive fibrosis. For decades it had no approved pharmacological treatment; lifestyle modification (caloric restriction, weight loss, exercise) was the only intervention with meaningful evidence. The convergence of the GLP-1 weight loss revolution with the hepatology field has produced the first disease-modifying treatments for MASH — a condition that affects an estimated 5–6% of all adults and is a leading cause of liver transplant listing.
GLP-1 agonists reduce liver fat and MASH severity through mechanisms beyond simple weight-induced caloric reduction. The liver has GLP-1 receptors, and direct hepatic GLP-1 signaling reduces de novo lipogenesis (new fat production) and increases fatty acid oxidation independently of weight loss. This was first suggested by preclinical work and supported clinically by the observation that liver fat reduction with GLP-1 agonists exceeds what would be expected from weight loss alone in matched comparisons.
Direct hepatic GLP-1 signaling: GLP-1 receptors expressed on hepatocytes activate AMPK and reduce SREBP-1c (the master regulator of lipogenic gene expression), directly suppressing de novo lipogenesis — the liver's synthesis of new triglycerides from carbohydrates. This mechanism operates independently of food intake reduction.
Visceral fat reduction: GLP-1 agonists preferentially reduce visceral adipose tissue, which drains via the portal vein directly to the liver. Visceral fat is the primary source of the free fatty acid flux into the liver that drives hepatic steatosis — reducing visceral fat reduces this substrate supply.
Insulin sensitization: Improved insulin sensitivity reduces hyperinsulinemia — chronically elevated insulin upregulates SREBP-1c and lipogenesis. By improving insulin signaling, GLP-1 agonists reduce this upstream driver of liver fat accumulation.
Anti-inflammatory effects: GLP-1 signaling in Kupffer cells (liver-resident macrophages) reduces NF-κB activation and pro-inflammatory cytokine production (TNF-α, IL-6) — directly addressing the "H" (hepatitis) in MASH. This may explain why fibrosis improves beyond what weight loss alone would predict.
Reduced caloric intake and weight loss: The systemic mechanisms of appetite suppression and weight loss contribute to MASH improvement by reducing overall metabolic substrate load, improving adipokine profiles, and reducing systemic insulin resistance.
The ESSENCE trial enrolled approximately 800 adults with biopsy-confirmed MASH (with fibrosis stages F2–F3) in a double-blind, placebo-controlled design. Participants received subcutaneous semaglutide 2.4mg weekly or placebo for 72 weeks. The co-primary endpoints — MASH resolution without worsening fibrosis AND fibrosis improvement ≥1 stage without MASH worsening — were both met:
These results are particularly significant because fibrosis — the scarring that determines long-term outcomes (cirrhosis, liver failure, hepatocellular carcinoma) — improved on biopsy, not just indirect markers. Biopsy-confirmed fibrosis improvement is the gold standard endpoint in MASH trials.
| Factor | Semaglutide (Wegovy) | Resmetirom (Rezdiffra) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist — systemic metabolic + direct hepatic effects | Selective thyroid hormone receptor β (THRβ) agonist — primarily hepatic lipid metabolism |
| FDA approval for MASH | 2024 — MASH with fibrosis (F2–F3) | March 2024 — non-cirrhotic MASH with moderate-to-advanced fibrosis (F2–F3) |
| MASH resolution in Phase 3 | 62% vs 34% placebo (ESSENCE) | ~30% (80mg) and ~40% (100mg) vs ~10% placebo (MAESTRO-NASH) |
| Fibrosis improvement | 37% vs 22% placebo | 24% (80mg) and 26% (100mg) vs 14% placebo |
| Weight effect | Significant weight loss (~13%) — additive metabolic benefit | Minimal systemic weight effect (hepatic-selective) |
| Cardiovascular benefit | Yes — SELECT trial (20% MACE reduction) | No established CV benefit data |
| Route | Weekly subcutaneous injection | Daily oral tablet |
| Best candidate | Patients with MASH + obesity + metabolic syndrome + CV risk | Patients with MASH + F2–F3 who prefer oral, no CV indication |
The approval of semaglutide for MASH represents a paradigm shift — fatty liver disease now has pharmacological treatment options where previously there were none. However, the context is critical:
Who should discuss this with their doctor: Adults with known NAFLD/MASH (any fibrosis stage), obesity with elevated liver enzymes, type 2 diabetes with fatty liver on imaging, or anyone with risk factors (metabolic syndrome, central obesity, insulin resistance) who has never had liver function evaluated. AST/ALT plus FibroScan is a reasonable non-invasive starting point before biopsy consideration.